Core Insights - The Hong Kong stock market has shown impressive performance this year, significantly boosting the performance of related thematic funds [1] - As of July 14, among 12,941 funds in the market, Hong Kong-themed funds have stood out, with notable performances from specific funds [1] - Fund managers anticipate a fluctuating upward trend for the Hong Kong stock market throughout the year, with distinct phases in market operation [1] Fund Performance - The fund "Huitianfu Hong Kong Advantage Selection A" leads the market with a 100% year-to-date net value growth rate, while "Bank of China Hong Kong Stock Connect Pharmaceutical A" ranks third with an 81.31% growth rate [1] - Among the top 20 funds by growth rate, six are Hong Kong-themed funds, indicating strong interest and performance in this sector [1] Market Trends - The first half of the year saw a market preference for assets with valuation elasticity, driven by liquidity easing [1] - In the second half, the investment focus is expected to shift towards cyclical stocks with stronger profit certainty [1]

2025年上半年，创新药板块的崛起成为投资市场的一大亮点。在政策支持、技术突破以及市场需求的多重驱动下，创 新药相关基金业绩表现突出，成为基金收益的关键驱动力，也成为主动权益为自己"正名"的关键一战。 创新药终于迎来了春天 主动权益正在回归 上半年收官，2025年上半场的激烈角逐尘埃落定。A股市场延续了震荡分化的特征，成长、消费、周期板块轮动加速。 一个显著的特点是，主动权益基金重新跑赢宽基指数。根据Wind的数据统计，今年上半年偏股基指数上涨7.86%，偏 股混基金收益率中位数为4.81%，75%的偏股混合型基金实现了正收益。从目前的表现看，今年大概率会成为主动权益 基金跑赢宽基指数的一年。 就着半年度的节点，我们也拉了一份上半年业绩TOP10的基金成绩单： 自今年4月9日触底反弹以来，A股、港股的创新药板块持续走强。截至6月30日，万得创新药概念指数涨超21%，恒生 创新药指数更是涨超66%。其中，张韡管理的汇添富香港优势精选A（470888）以86.48%的净值增长荣登2025年上半 年业绩榜首。 Wind数据显示，截至6月30日，汇添富香港优势精选A、中信建投北交所精选两年定开A、长城医药产业精选A跻 ...

Core Insights - The public fund market showed significant profitability in the first half of 2025, with 87% of funds achieving positive returns, highlighting a strong market recovery [1][9][10] - The top-performing funds were dominated by innovative drug and North Exchange theme funds, indicating a trend towards specialized investment strategies [2][3][4][5] Fund Performance - The best-performing fund was Huatai-PineBridge Hong Kong Advantage Selection A, with a net value growth of 86.48%, followed closely by CITIC Securities North Exchange Selection with 82.45% and Great Wall Pharmaceutical Industry Selection A with 75.18% [3][4] - Seven out of the top ten funds were heavily invested in innovative drugs, while two were focused on North Exchange themes, showcasing the effectiveness of concentrated investment strategies [4][5] Market Trends - The first half of 2025 saw a notable performance from sectors such as innovative drugs, North Exchange, humanoid robots, and new consumption, with these themes alternating in prominence [2][3][10] - Analysts predict that the positive trends for innovative drugs and North Exchange themes are likely to continue into the second half of the year, supported by structural opportunities in these sectors [7][8] Overall Market Dynamics - A total of 12,571 funds were analyzed, with 10,949 achieving positive returns, reflecting a broad-based recovery in the public fund market [9] - The market exhibited a "barbell" characteristic, with both high-growth technology stocks and low-valuation, high-dividend stocks performing well, particularly in the banking sector [10] Sector Performance - Certain sectors, such as real estate and food and beverage, underperformed, leading to lower returns for funds heavily invested in these areas [11] - The bond market transitioned from a bull market to a more volatile environment, resulting in weaker performance for fixed-income funds [11]

Core Viewpoint - The performance of the fund industry in the first half of 2025 has been strong, with significant returns driven by sectors such as pharmaceuticals and the North Exchange, despite challenges from tariff policies [2][4][7]. Fund Performance - The average return of all market fund products was 4.28%, with the best-performing fund achieving over 85% return and the worst losing more than 20%, resulting in a performance spread of over 106% [2]. - Notable funds include: - Huatai-PineBridge Hong Kong Advantage Selection A: 85.64% - CITIC Construction North Exchange Selection Two-Year Open A: 82.45% - Great Wall Pharmaceutical Industry Selection A: 75.18% - Huaxia North Exchange Innovative SMEs Selection Two-Year Open: 72.16% - Bank of China Hong Kong Stock Connect Pharmaceutical A: 70.08% [6][16]. Sector Highlights - The pharmaceutical sector has shown remarkable performance, with the core driver being the explosive growth of the Hong Kong innovative pharmaceutical sector [4][7]. - The North Exchange theme funds have also performed well, benefiting from ongoing reforms and the growth of specialized and innovative enterprises [7][19]. Fund Manager Insights - Fund managers have noted that the pharmaceutical industry is expected to continue demonstrating resilience and technological attributes over the next 2-3 years, with supportive policies for innovative drugs likely to improve conditions across various sectors [7][14]. - The performance of passive funds is increasingly challenging that of actively managed funds, with notable examples being: - Huaan Pharmaceutical Biotechnology A: 66.44% - Huatai-PineBridge National Index Hong Kong Stock Connect Innovative Drug ETF: 58.77% [3][11]. Market Outlook - The market is expected to shift from a risk-averse mindset to one focused on opportunities, with a broader range of sectors showing potential for growth, including technology and cyclical industries [18][19]. - Analysts predict a "dumbbell" structure for market opportunities in the second half of the year, highlighting both high-growth technology stocks and stable dividend-paying blue-chip stocks [19].

中基协会6月27日发布的最新公募基金市场数据显示，4月股基、债基、货基齐增，5月继续增长，公募 基金总规模再创新高达33.74万亿元。实际上，上半年公募基金市场整体规模稳居32万亿元上方，其中 权益类基金规模稳中有进。 一直以来，主动权益基金投资能力更是被行业视为基金公司的核心竞争力。随着2025年上半年正式收 官，公募基金净值表现的"中考"成绩成为了市场关注焦点。 半程冠军涨超85% 主动权益类基金（包括普通股票型基金、偏股混合型基金、平衡混合型基金、灵活配置型基金）的表现 突出。整体来看，6471只产品上半年实现浮盈（份额分开计算），占比81.6%。 其中，中信建投基金冷文鹏管理的中信建投北交所精选两年定开A/C以82.45%/82.1%的收益领跑上半 年，且该基金也在2025年6月30日创下历史净值新高。长城医药产业精选A/C、华夏北交所创新中小企 业精选两年定开、中银港股通医药A上半年收益均超70%，另有47只产品上半年收益超50%。 据悉，2025年一季度末，公募机构在北交所的重仓配置金额达到67.43亿元，较2024年末增长24.45%， 创历史新高。同时，配置北交所股票的公募机构数量也持续上升， ...

Group 1 - The core viewpoint of the article highlights the strong performance of actively managed equity funds, particularly those focused on the Beijing Stock Exchange and the pharmaceutical sector, with the top-performing fund achieving a return of 82.45% in the first half of 2025 [1][7]. - The top-performing funds include the CITIC Securities Beijing Stock Exchange Selected Two-Year Open A Fund, which is the only fund to exceed an 80% return, and other notable funds such as Great Wall Pharmaceutical Industry Selected A and Bank of China Hong Kong Stock Connect Pharmaceutical A, both exceeding 70% returns [2][7]. - The overall performance of the A-share and Hong Kong stock markets was positive, with major indices showing gains, particularly the North Exchange 50 Index, which rose by 39.45% [5][6]. Group 2 - Looking ahead to the second half of 2025, several fund companies express optimism about investment opportunities in the A-share market due to historically low valuation levels and supportive fiscal and monetary policies [3][10]. - Fund managers are particularly focused on sectors such as technology, innovative pharmaceuticals, and new consumption, anticipating structural opportunities in these areas [11][12]. - The Hong Kong market is expected to attract more investment due to the internationalization of the RMB and the listing of quality A-shares and overseas Chinese assets, which enhances its appeal [10]. Group 3 - Despite the overall positive outlook, some actively managed equity funds have underperformed, with the Qianhai Kaiyuan Artificial Intelligence A Fund showing a decline of 20.57%, marking it as the worst performer [9]. - Fund managers emphasize the importance of identifying structural opportunities in the market, particularly in sectors like AI, semiconductors, and military industry, as well as in cyclical industries that have seen significant price declines [11][12].

Core Viewpoint - The performance of active equity funds has shown a positive trend in the first half of the year, with over 70% achieving positive returns, particularly in the pharmaceutical and North Exchange sectors [1][2]. Group 1: Fund Performance - As of June 26, 2023, 6085 out of 7881 equity and mixed-asset funds reported positive returns, representing over 70% [2]. - The leading pharmaceutical fund, Huazhong Pharmaceutical Bio A, achieved a return of 75.91%, while several others exceeded 50% [2]. - North Exchange-themed funds also performed well, with the CITIC Construction North Exchange Select Fund yielding 80.71% [2]. Group 2: Market Outlook - Institutions maintain a cautiously optimistic view for the second half of the year, expecting a continuation of structural market characteristics [1][3]. - Key sectors for investment include technology, new consumption, and innovative pharmaceuticals, which are seen as having strong growth potential [1][4]. - The A-share market is anticipated to exhibit clear structural features, with the index likely oscillating around a central point [3]. Group 3: Investment Strategies - Investors are advised to focus on low-entry opportunities rather than chasing high prices, given the rapid rotation of market styles [4][5]. - Specific areas of interest include technology, new consumption, stable dividend stocks, and sectors benefiting from policy support [5]. - The expected policy measures are likely to positively influence investor sentiment and the equity market [5].

Group 1 - The A-share market has shown a rebound since April 7, with the Wind偏股混合型基金指数 rising over 11% as of June 17, indicating a recovery in active equity products [1][2] - Nearly 70% of active equity funds have turned positive in returns, with 3,079 out of 4,462 funds reporting gains, a significant increase from 10.8% on April 7 [2][3] - The top-performing funds are heavily invested in the pharmaceutical sector, with six out of the top ten funds focusing on this area, driven by Hong Kong innovative drug stocks [3][5] Group 2 - The top fund, 长城医药产业精选A, has achieved a 75.69% return year-to-date, followed closely by 中信建投北交所精选两年定开A and 永赢医药创新智选A with returns of 74% and 70.8% respectively [3] - The performance of the pharmaceutical sector is attributed to the strong showing of Hong Kong innovative drug stocks, which constitute a significant portion of the holdings in these funds [3][6] - Despite recent market corrections in popular sectors like innovative drugs and new consumption, industry experts believe that the long-term value remains intact, with ongoing support from national policies and market demand [5][6] Group 3 - The innovative drug sector has seen a year-to-date increase of 59.18%, while other sectors like humanoid robots and new consumption have also performed well, with gains exceeding 20% [5] - Recent corrections in these sectors are viewed as technical adjustments rather than a sign of a downturn, with analysts suggesting continued investment interest in innovative drugs due to their long-term growth potential [6][7] - The new consumption sector is experiencing a temporary pullback, but the underlying market conditions remain strong, as evidenced by positive consumption data during the recent 618 shopping festival [6][7]

根据数据，上述收益率排名前十的主动权益类基金，平均涨幅超过69%，除了汇添富香港优势精选A， 其他医药主题基金也表现亮眼。其中，分列收益率排行榜第二、三位的是长城医药产业精选A、永赢医 药创新智选A，收益率分别为87.73%、79.79%。 公募基金半年度业绩收官战进入倒计时，医药主题基金目前以碾压性优势席卷排行榜。 数据显示，截至6月14日，在收益率排名前十的主动权益类基金中，有9只为医药主题产品，暂居榜首的 汇添富香港优势精选A甚至以103.67%的收益率率先撞线"翻倍基"。半程冠军最终会花落谁家，市场正 拭目以待。 多位业内人士对证券时报记者表示，这场由创新药研发突破、港股流动性复苏、跨境BD交易重构估值 体系等多重因素驱动的医药投资盛宴，不仅改写了基金业绩的半年度排名格局，更折射出资本市场 对"中国创新力量"的重估与期待。 医药基金霸屏半年榜 6月已过半，主动权益基金的半年度业绩排名也即将出炉。年初至今，医药板块持续强势表现，多只医 药主题基金凭借精准布局和行业红利释放，实现了业绩爆发。不出意外，医药基金将成为半年度收益榜 单的最大赢家。 经历了多年连续下跌后，医药生物行业在2025年迎来了盈利与估值 ...

Group 1: Fundraising and Investment Trends - Several new pharmaceutical-themed funds have shortened their fundraising periods due to rapid stock price increases in innovative drugs, with some funds ending their fundraising early, such as the Dongfang Alpha Health Industry Fund, which closed on June 10 instead of June 13 [1] - The Ping An Hong Kong Stock Connect Medical Innovation Selected Fund also announced an early closure of its fundraising, originally set to end on June 25 [1] Group 2: Bond Fund Restrictions - Over ten public fund institutions, including China Merchants Fund and Dongfang Fund, announced restrictions on large subscriptions for certain bond funds, with varying limits on subscription amounts [2] - For instance, the Dongfang Zhenyu Bond Fund has a subscription limit of 10,000 yuan, while several funds under ICBC Credit Suisse have a limit of 10 million yuan for institutional investors starting June 11 [2] Group 3: Fund Performance Recovery - More than 60% of actively managed equity funds have recovered from previous performance declines, driven by sectors such as innovative drugs, new consumption, gold, and AI, with some funds seeing net value rebounds of over 30% in the past two months [4] - Funds like Changcheng Pharmaceutical Industry Selected A and Zhonghang Preferred Navigation A have shown significant performance improvements, with year-to-date returns exceeding 70% [4] Group 4: New Fund Share Classes - Public funds have been increasingly announcing the addition of new "niche" share classes, such as E shares for Ping An CSI A50 ETF and D shares for Jiahe Panheng Bond Fund, indicating a trend towards diversifying fund offerings [5] - The increase in "niche" share classes, particularly for fixed-income and index products, contrasts with the more common addition of B and C shares in the past [5] Group 5: Market Activity and ETF Performance - On June 11, the market experienced a rebound, with the Shanghai Composite Index rising by 0.52% and the Shenzhen Component Index by 0.83%, while the total trading volume was 1.26 trillion yuan, down by 159.9 billion yuan from the previous trading day [8] - Sectors such as rare metals and gaming saw significant gains, while biopharmaceuticals and communication services faced declines [8][9]